Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.

Ohsfeldt RL, Olsson AG, Jensen MM, Gandhi SK, Paulsson T.

J Med Econ. 2012;15(1):125-33. doi: 10.3111/13696998.2011.627073. Epub 2011 Nov 4.

PMID:
22050473
2.

Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.

Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J.

J Med Econ. 2010;13(3):428-37. doi: 10.3111/13696998.2010.499758.

PMID:
20662625
3.

Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.

Barrios V, Lobos JM, Serrano A, Brosa M, Capel M, Alvarez Sanz C.

J Med Econ. 2012;15 Suppl 1:45-54. doi: 10.3111/13696998.2012.726674. Epub 2012 Sep 12.

PMID:
22954062
4.

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.

PMID:
18691996
5.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

7.

Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.

Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L.

Curr Med Res Opin. 2008 Jun;24(6):1823-32. doi: 10.1185/03007990802144705. Epub 2008 May 15.

PMID:
18485270
9.

Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.

MacDonald GP.

J Am Osteopath Assoc. 2010 Aug;110(8):427-36. Erratum in: J Am Osteopath Assoc. 2010 Sep;110(9):508.

PMID:
20805548
10.

The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS.

Palmer SJ, Brady AJ, Ratcliffe AE.

Int J Clin Pract. 2003 Nov;57(9):792-800. Review.

PMID:
14686571
11.

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

Greving JP, Visseren FL, de Wit GA, Algra A.

BMJ. 2011 Mar 30;342:d1672. doi: 10.1136/bmj.d1672.

12.

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS, Stevenson M.

Eur J Prev Cardiol. 2012 Jun;19(3):474-83. doi: 10.1177/1741826711406616. Epub 2011 Apr 1.

PMID:
21460076
13.

Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.

Huse DM, Song X, Ozminkowski RJ, Maguire J, Williams SA, Borok GM, McDonough K.

Clin Ther. 2006 Sep;28(9):1425-42.

PMID:
17062315
14.

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events.

Gandhi SK, Jensen MM, Fox KM, Smolen L, Olsson AG, Paulsson T.

Clinicoecon Outcomes Res. 2012;4:1-11. doi: 10.2147/CEOR.S26621. Epub 2012 Jan 10.

16.
17.
18.

[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].

Lubsen J.

Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):216-7. Dutch. No abstract available.

PMID:
19271438
19.

Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal.

Pinto CG, Carrageta MO, Miguel LS.

Value Health. 2008 Mar-Apr;11(2):154-9. doi: 10.1111/j.1524-4733.2007.00224.x.

20.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

Items per page

Supplemental Content

Write to the Help Desk